Cephalosporin susceptibility among Neisseria gonorrhoeae Isolates-United States, 2000-2010

Morbidity and Mortality Weekly Report

Volumn 60, Issue 26, 2011, Pages 873-877

  del Rio, Carlos ^a,b   Hook, Edward W ^c   Whittington, William L H ^d   Kirkcaldy, Robert D ^e   Papp, John R ^e   Weinstock, Hillard ^e   Murray, Erin L ^f  

^a EMORY UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG EFFECT; FEMALE; GONORRHEA; HEALTH SURVEY; HOMOSEXUALITY; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGICAL EXAMINATION; NEISSERIA GONORRHOEAE; UNITED STATES;

ANTI-BACTERIAL AGENTS; CEFIXIME; CEFTRIAXONE; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; FEMALE; GONORRHEA; HOMOSEXUALITY, MALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; POPULATION SURVEILLANCE; UNITED STATES;

EID: 79960262635     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Fleming D, Wasserheit J. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Trans Infect 1999;75:3-17.
2. CDC. Fluoroquinolone-resistance in Neisseria gonorrhoeae, Hawaii, 1999, and decreased susceptibility to azithromycin in N. gonorrhoeae, Missouri, 1999. MMWR 2000;49:833-7.
3. CDC. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR 2007;56:332-6.
4. CDC. Sexually transmitted diseases treatment guidelines, 2010. MMWR 2010;59(No. RR-12)
5. CDC. Sexually transmitted disease surveillance supplement 2007, Gonococcal isolate surveillance project annual report 2007. Atlanta, GA: US Department of Health and Human Services, CDC; 2009.Availableathttp://www.cdc.gov/std/gisp2007/gispsurvsupp2007short.pdfinfiggraphic filenameifig1//infig. Accessed June 28, 2011.
6. National Committee for Clinical Laboratory Standards. Approved standard M100-38 performance standards for antimicrobial susceptibility testing. Wayne, PA: National Committee for Clinical Laboratory Standards;1998.
7. Wang S, Harvey A, Conner S, et al. Antimicrobial resistance for Neisseria gonorrhoeae in the United States, 1988 to 2003: the spread of fluoroquinolone resistance. Ann Intern Med 2007;147:81-8.
8. Tapsall J. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis 2009;22:87-91.
9. Unemo M, Golparian D, Syversen G, et al. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoeae treatment, Norway, 2010. Eurosurveillance 2010;15:19721-3.
10. Ohnishi M, Saika T, Hoshina S, et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis 2011;17:148-9.